Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 1.00 |
| ▸ | F9 | P00740 | 3/20 | 1.00 |
| ▸ | F11 | P03951 | 3/20 | 1.00 |
| ▸ | F7 | P08709 | 4/20 | 0.80 |
| ▸ | PLAU | P00749 | 7/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.60 |
| ▸ | PLG | P00747 | 6/20 | 0.60 |
| ▸ | F2 | P00734 | 6/20 | 0.60 |
| ▸ | PLAT | P00750 | 4/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1232343 | 0.91 | F10 (0.84) | F10F9F11F7PLAU | |
| SCHEMBL1232783 | 0.89 | F10 (1.00) | F10F9F11F7PLAU | |
| SCHEMBL9607771 | 0.80 | F10 (0.83) | F10F9F11F7PLAU | |
| SCHEMBL14519390 | 0.77 | PLAU (0.86) | F10F7PLAUPRSS1PLG | |
| SCHEMBL14355116 | 0.76 | PLAU (0.83) | F10F7PLAUPRSS1PLG | |
| SCHEMBL5517426 | 0.76 | PLAU (0.83) | F10F7PLAUPRSS1PLG | |
| SCHEMBL10140083 | 0.75 | F10 (0.60) | F10F9F11F7PLAU | |
| SCHEMBL14599555 | 0.75 | PLAU (0.77) | F10F7PLAUPRSS1PLG | |
| SCHEMBL24312880 | 0.74 | PLAU (0.81) | F10F7PLAUPRSS1PLG | |
| SCHEMBL7969986 | 0.74 | F10 (0.58) | F10F9F11F7PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462123-B1 | 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
| WO-2011017296-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F10 9/4885F9 1/4885F11 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.